Harmonet

Quick links to important sections

Harmonet

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Harmonet

Harmonet is a prescription-only medicine that is classified as an oral hormonal contraceptive pill, used primarily for pregnancy prevention in women of reproductive age.

Property Description
Active ingredient Ethinyl Estradiol, Gestodene
Form Coated Tablet
Pharmacological class Oral Contraceptive / Estrogen-Progestogen Combination
Common use Hormonal Contraception
Origin Synthetic Hormonal Preparation

Harmonet: Defining the Combined Contraceptive Pill

Harmonet belongs to the pharmacological class of Combined Hormonal Contraceptives (CHC), recognized as a reliable, reversible contraceptive method. The drug is classified as an Estrogen-Progestogen Combination for systemic use, which is a key distinguishing feature from progestin-only pills. The therapeutic use for oral hormonal contraception is clinically recognized.

What is Harmonet Made Of? Composition and Origin

Harmonet is a combination product containing the two synthetic hormonal preparation active ingredients: Ethinyl Estradiol (a synthetic estrogen) and Gestodene (a synthetic progestin). It is manufactured as a small, Coated Tablet for oral administration. The unique aspect is its progestin component, Gestodene, which is categorized as a potent third-generation progestin. Pharmacological studies have supported this specific composition for providing highly effective contraception.

General Purpose: Use as Hormonal Contraception

The general therapeutic purpose of Harmonet is exclusively hormonal contraception. It is used to achieve birth control by intentionally modulating the natural reproductive cycle. This benefit is realized through the combined suppression of the hormonal signals necessary for conception, providing a systemic method of preventing pregnancy. A typical use scenario involves providing women with a non-invasive, daily method of managing their reproductive health.

What side effects are possible with Harmonet?

Possible Side Effects and Safety Information

The safety profile of Harmonet, a combined hormonal contraceptive, is structured around high-level regulatory classifications detailing documented adverse reactions and specific safety constraints. All stated effects and classifications align strictly with official government regulatory documents.

Frequency-Classified Adverse Reactions

The regulatory documents classify potential adverse reactions into standardized frequency tiers:

  • Common (affecting 1 to 10 users in 100): Headache, migraine, nausea, breast pain, breast tenderness, and increases in body weight. These effects are typically associated with the use of combined hormonal pills.
  • Uncommon (affecting 1 to 10 users in 1,000): Vomiting, diarrhea, fluid retention, changes in libido, and skin reactions such as rash or urticaria.
  • Rare (affecting 1 to 10 users in 10,000): Venous Thromboembolism (VTE), Arterial Thromboembolism (ATE), and hypersensitivity reactions.

Serious Adverse Reactions and Key Safety Constraints

Serious adverse reactions officially documented in regulatory labeling include Venous Thromboembolism (VTE), such as deep vein thrombosis and pulmonary embolism, and Arterial Thromboembolism (ATE), including stroke and myocardial infarction. Liver tumours and hypertension are also documented.

Time-Related Patterns: The risk of VTE is highest during the first year of use and is also elevated when re-starting the medication after a break of four weeks or longer.

Population-Specific Risk: Regulatory texts note that the risk of serious cardiovascular events is significantly increased in individuals who smoke, particularly those over 35 years of age. Use is contraindicated in individuals with a history of or pre-existing predisposition to thromboembolic disorders or severe hepatic impairment. These official classifications structure the understanding of the product’s safety profile by defining the most critical, albeit rare, risks and the demographic factors that modify them.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdosage for this combined oral contraceptive, which contains Ethinyl Estradiol and Gestodene, is derived strictly from official government regulatory documents.

Regulatory sources indicate that acute overdosage is generally not likely to be life-threatening. The manifestations documented are primarily related to the expected hormonal effects.

Documented Overdose Manifestations Emergency Response Mandate
Nausea, Vomiting Seek immediate medical attention
Vaginal bleeding (withdrawal bleeding/spotting) Contact a Poison Control Center
Breast tenderness, Headache Treatment is symptomatic and supportive

Official prescribing information states that the most commonly observed symptoms following the ingestion of several pills are gastrointestinal disturbances, such as nausea and vomiting. Vaginal bleeding, including withdrawal bleeding or spotting, is also a specifically documented manifestation, particularly in adolescents and young women.

No specific antidote is known for an overdose of this combination product. Therefore, clinical management, as described by regulatory authorities, relies on symptomatic and supportive treatment. Regardless of the perceived severity of symptoms, individuals are officially required to seek immediate medical attention and contact emergency services for clinical assessment and guidance.

Therapeutic Uses of Harmonet

What Harmonet Treats: Main Uses and Benefits

Harmonet is commonly used as an established method of hormonal contraception for women of reproductive age, providing an ongoing method for long-term management of fertility and supports reproductive autonomy. Combined pills may be part of symptomatic management applied across domains where additional symptomatic support is needed.

The therapeutic use of this medication is relevant for easing symptoms that may become intense or disruptive, specifically targeting conditions characterized by periods of heightened symptoms. It is used for managing painful periods (dysmenorrhea), is relevant for easing the burden of heavy menstrual bleeding, and is applied in addressing androgen-related manifestations such as hormonal acne and hirsutism.

“The combined hormonal profile is relevant for easing symptoms that interfere with daily comfort.”

In clinical settings where patients experience these recurrent or episodic manifestations, Harmonet contributes to improved comfort during symptomatic periods and supports the patient by addressing symptoms related to systemic imbalance.

Quick Fact: Relief for Menstrual Discomfort
Common Use: Applied in scenarios where additional management of discomfort is required, is applied in addressing symptoms related to physical discomfort.

Regulatory References

  1. NIH StatPearls overview on Oral Contraceptive Pills

Eligibility and Restrictions for Use

Harmonet (Ethinyl Estradiol/Gestodene) is a prescription-only combined hormonal contraceptive whose eligibility is strictly defined by regulatory bodies. It is primarily established for use in adult women of reproductive age.

The medicine is contraindicated (must not be used) in women with a current or history of venous or arterial thromboembolism (such as DVT, Pulmonary Embolism, Myocardial Infarction, or Stroke), as well as a known hereditary predisposition for blood clots. It is strictly contraindicated in patients with severe liver disease or the presence of liver tumours, and in those with known or suspected hormone-sensitive malignancies like breast cancer.

Eligibility is also restricted by physiological status and age. Harmonet is contraindicated during known or suspected pregnancy. It is not recommended for nursing mothers (breastfeeding) or for use in postmenopausal women. Additionally, the medicine must be discontinued before any major planned surgery or during any period of prolonged immobilisation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This product’s official interaction profile is characterized by two main concerns: a risk of reduced contraceptive effectiveness and a risk of increased plasma concentrations of the hormonal components or of co-administered drugs.

Interacting Product Category Official Constraint or Requirement
Hepatic Enzyme Inducers (e.g., certain anticonvulsants, rifampicin) Requires use of a concurrent barrier contraceptive method during the use of the enzyme-inducing medicine and for 28 days after its discontinuation, due to increased clearance of the contraceptive steroids.
Hepatitis C Virus (HCV) Combination Regimens (e.g., ombitasvir/paritaprevir/ritonavir pm dasabuvir) Contraindicated for concomitant use, as co-administration can significantly increase the plasma concentration of ethinylestradiol, potentially leading to elevated transaminase (ALT) levels.
Broad-Spectrum Antibiotics (e.g., ampicillin, tetracyclines) Requires an additional barrier method during antibiotic use and for 7 days after discontinuation, based on the theoretical possibility of interference with the enterohepatic circulation of estrogen.
Drugs Subject to Glucuronidation (e.g., lamotrigine) Oral contraceptives may inhibit the glucuronidation of certain co-administered drugs, which can lead to increased plasma concentrations of the other drug, necessitating clinical monitoring.

These restrictions and requirements are officially mandated to manage interactions that primarily affect the metabolism and plasma levels of the contraceptive hormones (ethinylestradiol and gestodene) or the co-administered drug, ensuring that officially designated constraints are followed.

Mechanism of Action

Central Regulation of the HPO Axis

This primary mechanism involves the drug's components acting as agonists at hormone receptors in the brain to disrupt the Hypothalamus-Pituitary-Ovarian (HPO) axis. This action effectively suppresses the upstream signals (FSH and LH) required for egg maturation and release. The resulting physiological consequence of this central signaling modification is the prevention of ovulation (anovulation).


Peripheral Alteration of Reproductive Fluids

The progestogen component acts on the cervix to modify the biophysical properties of the natural secretions there. This mechanism leads to the thickening and increased viscosity of cervical mucus, creating a localized physical barrier that restricts the movement of sperm through the cervical canal.


Modulating Uterine Lining Receptivity

Simultaneously, the hormones influence the development and stability of the inner lining of the womb (endometrium). This action results in a less developed, thinner lining, which makes the environment unfavorable for implantation, which contributes to the drug's overall mechanistic consequence.

Dosage and Administration Information

Harmonet is an oral medicine that is used according to a standardized cyclic regimen established in prescribing information. The medication is manufactured as a Coated Tablet and is administered exclusively by the oral route. The fixed daily dose is one tablet, which contains 75 mu g Gestodene and 20 mu g Ethinylestradiol.

Official Administration Schedule

The usage pattern is defined by a 28-day cycle. This consists of taking one tablet daily for 21 consecutive days, followed by a 7-day tablet-free interval. The next pack must be started immediately following this seven-day break, ensuring continuous adherence to the schedule. Tablets should be taken at about the same time each day with a small amount of liquid, irrespective of mealtimes.

Administration Constraint Labeled Instruction
Pediatric Use Not indicated for use before menarche (onset of menstruation).
Postpartum Initiation Should begin no sooner than the 28th postpartum day.
Gastrointestinal Upset Vomiting or severe diarrhea occurring within 4 hours of administration necessitates application of the missed dose protocol, as absorption may be incomplete.

Handling Missed Timing

Detailed procedural instructions dictate the management of a missed tablet based on the duration of delay. Specific actions are required if the tablet is missed by less than 12 hours versus a delay of more than 12 hours in order to maintain the integrity of the usage protocol. This fixed cyclic use and timing requirement structure the entire course of administration, ensuring consistent application of the labeled dose.

Recent Clinical Evidence

Harmonet is a combined oral contraceptive (COC) that contains ethinylestradiol (20 micrograms) and gestodene (75 micrograms). Its clinical use has been the subject of regulatory review and epidemiological research, primarily focusing on its effectiveness and its associated risk of venous thromboembolism (VTE).

Contraceptive Efficacy and Risk

Clinical trials have established the drug's effectiveness as an oral contraceptive, comparable to other combined oral contraceptives when used consistently and correctly. The primary mechanism of action involves preventing ovulation, altering cervical mucus, and changing the uterine lining.

However, research classifies the gestodene/ethinylestradiol combination in Harmonet as a third-generation COC.

  • VTE Risk: The use of any COC increases the risk of VTE compared with no use. Studies have determined that gestodene-containing COCs may be associated with up to twice the level of VTE risk compared to products containing older progestins, such as levonorgestrel (considered to have the lowest risk). For instance, it is estimated that out of 10,000 women using a gestodene-containing COC, approximately 9–12 may develop VTE in one year, compared to about 6 who use a levonorgestrel-containing COC.

Non-Contraceptive Effects

Research has explored secondary effects on user health and compliance:

  • Weight and Body Composition: A prospective open-label study evaluated the effect of this low-dose oral contraceptive on body fat and composition over six treatment cycles. No significant change was observed in weight, Body Mass Index (BMI), fat distribution, or overall body composition in the study group compared to non-users.
  • Cycle Control: Clinical trial data on cycle control, including the occurrence of breakthrough bleeding or spotting, have generally shown favorable results comparable to other monophasic COCs.

Frequently Asked Questions (FAQ)

Common questions about Harmonet (FAQ)


Q: What is the difference between Harmonet and other 'pill' medications?

Harmonet is a Combined Hormonal Contraceptive (CHC) that contains the progestogen gestodene, which is categorized as a third-generation progestin. Official studies indicate that CHCs containing gestodene may be associated with up to twice the risk of venous thromboembolism (VTE—or blood clots) compared to those containing older progestins like levonorgestrel.


Q: Is it normal to feel slightly nauseous when first starting Harmonet?

Nausea and vomiting are listed in regulatory documents as common side effects associated with this medication. Patient information often notes that these feelings may be especially likely to occur or be most noticeable during the first few months after beginning use.


Q: Does using Harmonet require any special monitoring by a doctor?

Regulatory guidelines often advise for regular medical check-ups while using Harmonet. Monitoring typically includes assessing your blood pressure, and for individuals with certain risk factors, such as high blood lipid levels, more specialized monitoring may be indicated.


Q: Are there any long-term health concerns associated with Harmonet use?

Serious health concerns officially documented, though rare, include an elevated risk of Venous and Arterial Thromboembolism (VTE/ATE) and liver tumours. Long-term use is also associated with a small, manageable increase in the risk of breast and cervical cancer, which is a reason for continued regular screening and check-ups.


Q: What is the success rate described in the research for Harmonet?

Clinical trials confirm its contraceptive effectiveness is comparable to other Combined Oral Contraceptives (COCs) when used consistently. The risk of VTE with gestodene-containing products is officially estimated at 9–12 cases per 10,000 women who use them for one year.


Q: Can Harmonet affect mood or mental health?

Yes, official product information lists both changes in libido and depression as potential side effects. Information regarding persistent changes in mood or mental health is typically reviewed with a healthcare provider.


Q: Why is it necessary to take Harmonet at the same time each day?

The product literature emphasizes that taking the tablet at about the same time each day is described as essential for maintaining consistent hormone levels. This regular schedule is necessary to preserve the product’s contraceptive efficacy throughout the cycle.


Q: Is Harmonet associated with changes in skin, such as acne?

Official side effect lists note general skin reactions such as rash or hives. However, formulations containing these specific components (estrogen/progestin) are also sometimes used in clinical practice to manage conditions like hormonal acne.


Q: How is the mechanism of action of Harmonet described simply?

It works in three primary ways to prevent pregnancy: it stops the ovary from releasing an egg (ovulation), thickens the natural mucus in the cervix to block sperm, and alters the lining of the womb (endometrium) to prevent a fertilized egg from implanting.


Q: Does official research evidence cover long-term outcomes for Harmonet?

Yes, official safety reviews and guidelines have examined long-term use. Studies indicate that the benefits of continued use generally outweigh the risks for healthy women up to the age of menopause who do not have contraindicating medical conditions.


Q: How long does it typically take for Harmonet to start working?

When starting the pill on days 2 through 7 of the menstrual cycle, regulatory documents indicate that the use of an additional non-hormonal back-up method is advised for the first 7 days of tablet-taking. This is to ensure reliable contraceptive protection is established.


Q: Are there any common foods or supplements that interact with Harmonet?

While the focus of interaction warnings is on other medicines, general information advises caution regarding certain foods. For instance, substances like Grapefruit Juice have components that may interfere with how the contraceptive hormones are metabolized by the body.


Q: Does the efficacy of Harmonet change over time?

The risk of Venous Thromboembolism (VTE) is known to be highest during the first year of use or when restarting after a break of four weeks or more. Contraceptive efficacy remains high as long as the tablets are taken correctly according to the labeled regimen.


Q: Is Harmonet considered a 'low-dose' option?

Harmonet contains 20mu g of ethinylestradiol. Formulations with this dose are generally classified by regulators and health authorities as a low-dose Combined Oral Contraceptive formulation.


Q: How long can a person safely continue using Harmonet?

Official guidelines indicate that Harmonet is generally considered safe for continuous use in healthy women up to the age of menopause who do not have contraindications. However, the risk of serious side effects is known to increase with age and the presence of other risk factors.


Q: Is it true that Harmonet can help with non-cycle-related symptoms?

Yes, in addition to contraception, official clinical guidance indicates that formulations with these components are used to help manage conditions like hormonal acne and regulate symptoms associated with Polycystic Ovary Syndrome (PCOS).


Q: Is the process for discontinuing Harmonet straightforward?

The product literature mandates that the medication be discontinued before any major planned surgery or during prolonged periods of immobilization. For general, permanent discontinuation, official guidance states that the need for specific medical advice should be considered when planning to stop use.


Q: What does the patient information leaflet say about alcohol use with Harmonet?

The product information does not list a direct contraindication for alcohol use. However, general cautions are advised, as alcohol consumption could affect how the central nervous system responds when certain interacting medicines or herbs are also being used.


Q: Are vision changes ever linked to the use of Harmonet?

Yes, the official patient leaflet includes vision changes as a potential warning sign. Sudden trouble seeing in one or both eyes or painless blurring of vision are listed as potential symptoms of a rare blood clot in the eye (Retinal vein thrombosis). These symptoms are identified as requiring urgent medical review.


Q: Can herbal remedies, like St. John's wort, interact with Harmonet?

Yes, official documentation explicitly lists St. John's Wort as a substance that interacts with Harmonet. It is a known enzyme inducer that can significantly reduce the blood levels and effects of the hormonal components, leading to a risk of breakthrough bleeding and potential contraceptive failure.


Q: What if I take two doses of Harmonet close together by accident?

The product instructions for a missed active tablet require taking the last missed tablet immediately, even if this means taking two tablets in one day. Specific advice for an accidental overdose beyond this scenario is typically obtained from a healthcare professional.

How should Harmonet be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents specify strict conditions for the storage and disposal of Harmonet to maintain its stability and protect the environment.

Requirement Area Official Instructions
Temperature Constraint Store the medicine at a temperature below 30°C.
Protection Keep the tablets in the original blister pack and outer carton to protect them from light and moisture.
Shelf-Life Do not use the medicine after the expiry date (EXP) printed on the packaging.
Child Safety Keep Harmonet out of the sight and reach of children.
Disposal Do not dispose of expired or unused medicine via household waste or wastewater. It must be returned to a pharmacist for proper disposal to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Harmonet found in:

A-Z Index: